{"protocolSection": {"identificationModule": {"nctId": "NCT00558064", "orgStudyIdInfo": {"id": "1235.13"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Filtered Trial for Amlodipine Non-responder", "officialTitle": "Filtered Trial for Amlodipine Non-responder"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-29", "studyFirstSubmitQcDate": "2007-11-12", "studyFirstPostDateStruct": {"date": "2007-11-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-11-10", "resultsFirstSubmitQcDate": "2010-01-07", "resultsFirstPostDateStruct": {"date": "2010-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-24", "lastUpdatePostDateStruct": {"date": "2014-07-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 531, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "telmisartan+amlodipine"}, {"type": "DRUG", "name": "amlodipine"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "timeFrame": "Baseline and 8 Weeks"}], "secondaryOutcomes": [{"measure": "Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "timeFrame": "Baseline and 8 Weeks"}, {"measure": "Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough diastolic blood pressure was \\<90 mmHg or decreased from reference baseline by \\>=10 mmHg at 8 weeks", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks", "description": "Adequate response defined that seated trough systolic blood pressure was \\<140 mmHg or decreased from reference baseline by \\>=20 mmHg at 8 weeks (0 percent at baseline)", "timeFrame": "8 weeks"}, {"measure": "Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Optimal, normal, high normal blood pressure were defined as follows:\n\n* Optimal: Systolic blood pressure (SBP) \\< 120 mmHg and diastolic blood pressure (DBP) \\< 80 mmHg\n* Normal: SBP \\>= 120 mmHg or DBP \\>= 80 mmHg and SBP \\< 130 mmHg and DBP \\< 85 mmHg\n* High normal: SBP \\>= 130 mmHg or DBP \\>= 85 mmHg and SBP \\< 140 mmHg and DBP \\< 90 mmHg\n* No: SBP \\>= 140 mmHg and DPB \\>= 90 mmHg", "timeFrame": "8 weeks"}, {"measure": "Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG", "description": "Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "timeFrame": "First administration of randomised treatment to 24 hours post last dose of randomised treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Essential hypertensive patients satisfying all of the following criteria;\n2. Male or Female\n3. Age \\> 20 years\n4. Outpatient\n5. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications\n6. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.\n\nExclusion Criteria:\n\n1. Taking four or more anti-hypertensive medications\n2. Secondary hypertension\n3. Mean seated diastolic blood pressure (DBP) \\> 114 mmHg and/or mean seated systolic blood pressure (SBP) \\> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \\< 90 mmHg at Visit 3.\n4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias\n5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV\n6. History of myocardial infarction or cardiac surgery within last 6 months\n7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months\n8. History of unstable angina within last 3 months\n9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve\n10. History of stroke or transient ischemic attack within last 6 months\n11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy\n12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors\n13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs\n14. Hepatic and/or renal dysfunction\n15. Diagnosed biliary atresia or cholestasis\n16. Hyperkalemia\n17. Dehydration\n18. Sodium deficiency\n19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)\n20. Patients who cannot change to the restricted administration and dosage during study period\n21. Pre-menopausal women who meet any one of the following 1 - 3:\n\n    * Pregnant or possibly pregnant (1)\n    * Nursing (2)\n    * Desire to become pregnant during study period (3)\n22. Drug or alcohol dependency\n23. Complication of malignant tumour or a disease requiring immunosuppressants\n24. Compliance of \\< 80% or \\> 120% during the run-in period\n25. Receiving any investigational therapy within 3 months\n26. Judged to be inappropriate by the investigator or the sub-investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1235.13.037 Boehringer Ingelheim Investigational Site", "city": "Azumino, Nagano", "country": "Japan"}, {"facility": "1235.13.023 Boehringer Ingelheim Investigational Site", "city": "Higashiosaka, Osaka", "country": "Japan"}, {"facility": "1235.13.021 Boehringer Ingelheim Investigational Site", "city": "Itabashi-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "1235.13.014 Boehringer Ingelheim Investigational Site", "city": "Kashihara, Osaka", "country": "Japan"}, {"facility": "1235.13.038 Boehringer Ingelheim Investigational Site", "city": "Kitaazumi-gun, Nagano", "country": "Japan"}, {"facility": "1235.13.009 Boehringer Ingelheim Investigational Site", "city": "Kiyose, Tokyo", "country": "Japan"}, {"facility": "1235.13.041 Boehringer Ingelheim Investigational Site", "city": "Kobe, Hyogo", "country": "Japan"}, {"facility": "1235.13.035 Boehringer Ingelheim Investigational Site", "city": "Komoro, Nagano", "country": "Japan"}, {"facility": "1235.13.003 Boehringer Ingelheim Investigational Site", "city": "Koriyama, Fukushima", "country": "Japan"}, {"facility": "1235.13.004 Boehringer Ingelheim Investigational Site", "city": "Koriyama, Fukushima", "country": "Japan"}, {"facility": "1235.13.027 Boehringer Ingelheim Investigational Site", "city": "Koriyama, Fukushima", "country": "Japan"}, {"facility": "1235.13.007 Boehringer Ingelheim Investigational Site", "city": "Koshigaya, Saitama,", "country": "Japan"}, {"facility": "1235.13.008 Boehringer Ingelheim Investigational Site", "city": "Koto-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.66667, "lon": 139.81718}}, {"facility": "1235.13.005 Boehringer Ingelheim Investigational Site", "city": "Matsudo, Chiba", "country": "Japan"}, {"facility": "1235.13.026 Boehringer Ingelheim Investigational Site", "city": "Mito, Ibaraki", "country": "Japan"}, {"facility": "1235.13.013 Boehringer Ingelheim Investigational Site", "city": "Nagoya, Aichi", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "1235.13.016 Boehringer Ingelheim Investigational Site", "city": "Okayama, Okayama,", "country": "Japan"}, {"facility": "1235.13.040 Boehringer Ingelheim Investigational Site", "city": "Osaka, Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "1235.13.025 Boehringer Ingelheim Investigational Site", "city": "Saitama, Saitama", "country": "Japan"}, {"facility": "1235.13.001 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.024 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.028 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.030 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.031 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.033 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.034 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1235.13.002 Boehringer Ingelheim Investigational Site", "city": "Sendai, Miyagi", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "1235.13.018 Boehringer Ingelheim Investigational Site", "city": "Sendai, Miyagi", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "1235.13.019 Boehringer Ingelheim Investigational Site", "city": "Sendai, Miyagi", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "1235.13.036 Boehringer Ingelheim Investigational Site", "city": "Shimoina-gun, Nagano", "country": "Japan"}, {"facility": "1235.13.042 Boehringer Ingelheim Investigational Site", "city": "Shinjuku-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "1235.13.010 Boehringer Ingelheim Investigational Site", "city": "Shinjyuku-ku, Tokyo", "country": "Japan"}, {"facility": "1235.13.011 Boehringer Ingelheim Investigational Site", "city": "Shinjyuku-ku,Tokyo", "country": "Japan"}, {"facility": "1235.13.022 Boehringer Ingelheim Investigational Site", "city": "Shizuoka, Shizuoka", "country": "Japan"}, {"facility": "1235.13.015 Boehringer Ingelheim Investigational Site", "city": "Suita, Osaka,", "country": "Japan"}, {"facility": "1235.13.017 Boehringer Ingelheim Investigational Site", "city": "Takamatsu, Kagawa", "country": "Japan"}, {"facility": "1235.13.029 Boehringer Ingelheim Investigational Site", "city": "Takamatsu, Kagawa", "country": "Japan"}, {"facility": "1235.13.032 Boehringer Ingelheim Investigational Site", "city": "Takamatsu, Kagawa", "country": "Japan"}, {"facility": "1235.13.012 Boehringer Ingelheim Investigational Site", "city": "Takaoka, Toyama", "country": "Japan"}, {"facility": "1235.13.039 Boehringer Ingelheim Investigational Site", "city": "Takaoka,Toyama", "country": "Japan"}, {"facility": "1235.13.020 Boehringer Ingelheim Investigational Site", "city": "Tsuchiura, Ibaraki", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "FG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "269"}, {"groupId": "FG001", "numSubjects": "262"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "264"}, {"groupId": "FG001", "numSubjects": "257"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "No visit within allowance period", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "BG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "269"}, {"groupId": "BG001", "value": "262"}, {"groupId": "BG002", "value": "531"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57", "spread": "9.6"}, {"groupId": "BG001", "value": "56", "spread": "9.9"}, {"groupId": "BG002", "value": "56.5", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "148"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "197"}, {"groupId": "BG001", "value": "186"}, {"groupId": "BG002", "value": "383"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 Weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.56", "spread": "0.61"}, {"groupId": "OG001", "value": "4.45", "spread": "0.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "5.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.98", "ciUpperLimit": "6.23", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.57", "estimateComment": "Difference calculated as telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination minus amlodipine 5 mg monotherapy"}]}, {"type": "SECONDARY", "title": "Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)", "description": "The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 Weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.04", "spread": "0.88"}, {"groupId": "OG001", "value": "5.77", "spread": "0.88"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "68.1"}, {"groupId": "OG001", "value": "47.1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)", "description": "Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.1"}, {"groupId": "OG001", "value": "45.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Adequate response defined that seated trough diastolic blood pressure was \\<90 mmHg or decreased from reference baseline by \\>=10 mmHg at 8 weeks", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.5"}, {"groupId": "OG001", "value": "50.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks", "description": "Adequate response defined that seated trough systolic blood pressure was \\<140 mmHg or decreased from reference baseline by \\>=20 mmHg at 8 weeks (0 percent at baseline)", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.5"}, {"groupId": "OG001", "value": "58.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)", "description": "Optimal, normal, high normal blood pressure were defined as follows:\n\n* Optimal: Systolic blood pressure (SBP) \\< 120 mmHg and diastolic blood pressure (DBP) \\< 80 mmHg\n* Normal: SBP \\>= 120 mmHg or DBP \\>= 80 mmHg and SBP \\< 130 mmHg and DBP \\< 85 mmHg\n* High normal: SBP \\>= 130 mmHg or DBP \\>= 85 mmHg and SBP \\< 140 mmHg and DBP \\< 90 mmHg\n* No: SBP \\>= 140 mmHg and DPB \\>= 90 mmHg", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after the start of the double-blind maintenance period on final dose.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "257"}]}], "classes": [{"title": "Optimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.0"}, {"groupId": "OG001", "value": "1.6"}]}]}, {"title": "Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.3"}, {"groupId": "OG001", "value": "9.7"}]}]}, {"title": "High Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.6"}, {"groupId": "OG001", "value": "23.0"}]}]}]}, {"type": "SECONDARY", "title": "Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG", "description": "Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.", "populationDescription": "Treated set: Patients randomised to the double-blind treatment period who took at least one dose either of T40+A5 or A5 during the double-blind treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First administration of randomised treatment to 24 hours post last dose of randomised treatment", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning"}, {"id": "OG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "262"}]}], "classes": [{"title": "Alanine aminotransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate aminotransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood creatine phosphokinase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Blood potassium increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Blood urine present", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Liver function test abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Bradycardia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First administration of randomised treatment to 24 hours post last dose of randomised treatment", "eventGroups": [{"id": "EG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "description": "T40/A5 tablet, oral, once daily in the morning", "seriousNumAffected": 1, "seriousNumAtRisk": 269, "otherNumAffected": 25, "otherNumAtRisk": 269}, {"id": "EG001", "title": "Amlodipine 5 mg Monotherapy", "description": "A5 capsule, oral, once daily in the morning", "seriousNumAffected": 2, "seriousNumAtRisk": 262, "otherNumAffected": 34, "otherNumAtRisk": 262}], "seriousEvents": [{"term": "Guillain-Barre syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 262}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 262}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 262}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 269}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 262}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract"}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}, {"id": "C000548840", "term": "Telmisartan amlodipine combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M261345", "name": "Telmisartan amlodipine combination", "asFound": "Pressure, pulse", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}